PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI  + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer

Gastric or gastro-oesophageal junction (GEJ) adenocarcinomas present poor overall survival (OS). First-line chemotherapy regimen for patients with HER2-negative tumours is based on a doublet or triplet of fluoropyrimidine plus platinum salt ± taxane. Second-line chemotherapy (Docetaxel or Irinotecan) improves OS which nonetheless remains poor (around 5 months). The first results of immune checkpoint inhibitors (anti-PD-1) combined with chemotherapy in metastatic gastric and GEJ cancers were discordant in recent phase III trials.

Source: Digestive and Liver Disease - December 21, 2020 Category: Gastroenterology Authors: Camille Evrard, Christophe Louvet, Farid EL Hajbi, Fr édéric DI Fiore, Karine LE Malicot, Thomas Aparicio, Olivier Bouché, Pierre Laurent-Puig, Frédéric Bibeau, Thierry Lecomte, Astrid Lièvre, Rosine Guimbaud, Stefano Kim, Aziz Zaanan, Harry Sokol, Tags: Progress Report Source Type: research